Bank of America’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Bank of America’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-260,000	Closed	-$2.63M	–	8583
2022 Q4	$2.63M	Hold	260,000	–	–	﹤0.01%	4010
2022 Q3	$2.57M	Hold	260,000	–	–	﹤0.01%	4049
2022 Q2	$2.54M	Hold	260,000	–	–	﹤0.01%	4078
2022 Q1	$2.53M	Buy	+260,000	New	+$2.53M	﹤0.01%	4359

Bank of America's EBAC Position: Q1 2023 in Review

Bank of America sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 260,000 shares — an estimated $2.63M sold.

Bank of America first reported a position in EBAC in Q1 2022 and held it in 4 quarters. The position peaked at $2.63M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Bank of America reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Bank of America sold 260,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $2.63M.
Bank of America first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Bank of America's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.63M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.